CTCE-9908
| Code | Size | Price |
|---|
| TAR-TP2051-1mg | 1mg | £257.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
CXCR4 antagonist; induces mitotic catastrophe in ovarian cancer cells. Displays additive cytotoxic effects when given with taxol. Enhances the efficacy of docetaxel in a mouse model.
CAS:
1030384-98-5
Formula:
C86H147N27O23
Molecular Weight:
1927.27
Purity:
0.98
SMILES:
0
References
Hassan et al (2011) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or doce. in a transgenic mouse model. Int.J.Cancer. 129 225 PMID:
Kwong et al (2009) An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol.Cancer Ther. 8 1893 PMID:
Faber et al (2007) The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J.Biomed.Biotechnol. 2007 26065 PMID: